A 10.0 KB Excel file authored by Ruiyue Wu details a single case of HER2-low metastatic breast cancer treated with the antibody-drug conjugate disitamab vedotin (RC-48). The data, last updated in May 2026, reports a time to treatment failure of 4.6 months and tracks dynamic changes in HER2 status and tumor response over a 13.7-month survival period. This case underscores the potential of RC-48 in later-line treatment and the importance of repeat biopsy.
Use Cases
- Analyzing the clinical response timeline of a novel ADC based on reported time to treatment failure and survival duration.
- Studying the biological heterogeneity of metastatic breast cancer based on the described dynamic changes in HER2 status.
- Evaluating the potential of later-line ADC therapy based on the reported tumor marker and imaging improvements.
- Assessing the importance of repeat biopsy in treatment planning based on the case's evolution of HER2 expression.
Strengths
- Data is licensed under CC-BY-4.0, permitting broad reuse and sharing.
- The description provides specific clinical metrics, including a 4.6-month time to treatment failure and a 13.7-month survival period.
- The case report details a clinically relevant subgroup (HER2-low) and a novel therapeutic agent (RC-48).
Limitations
- Row count is unknown, which may limit suitability assessment.
- Column-level documentation is absent; field semantics must be inferred after download.
- The dataset is extremely small (10.0 KB), representing a single case report, which limits statistical analysis.
Provenance
- Source
- figshare
- Collection Method
- Likely contains manually recorded clinical observations from a single patient case.
- Time Range
- The clinical timeline described spans from initial diagnosis to death over 13.7 months following RC-48 initiation.
- Freshness
- Last updated 2026-05-04 04:16:48; freshness should be verified.
- Geography
- null